ライフサイエンスコーパス: peginterferon alfa-2a

1 for standard-dose peginterferon alfa-2b vs. peginterferon alfa-2a).

2 HCV when dosed alone or in combination with peginterferon alfa-2a.

3 -associated Kaposi sarcoma were treated with peginterferon alfa-2a.

4 ed volunteers were treated for 12 weeks with peginterferon alfa-2a.

5 lfa-2b, and 31.5% (95% CI, 27.9 to 35.2) for peginterferon alfa-2a.

6 ween standard-dose peginterferon alfa-2b and peginterferon alfa-2a.

7 Patients were retreated with peginterferon alfa-2a 180 microg/wk plus ribavirin 1000-

8 n therapy are not significantly higher using peginterferon alfa 2a (180 microg/wk; 43%) or peginterfe

9 eive simeprevir (150 mg once daily, orally), peginterferon alfa 2a (180 mug once weekly, subcutaneous

10 then 750 mg every 8 hours) for 12 weeks and peginterferon alfa-2a (180 microg per week) and ribaviri

11 ntrol group (called the PR48 group) received peginterferon alfa-2a (180 microg per week) and ribaviri

12 y assigned to receive one of three regimens: peginterferon alfa-2a (180 microg per week) plus ribavir

13 included nitazoxanide (500 mg) twice daily, peginterferon alfa-2a (180 microg) once weekly, and weig

14 ients randomized to the conventional dose of peginterferon alfa-2a (180 microg/week) for the pairwise

15 interferon +/- ribavirin were retreated with peginterferon alfa-2a (180 microg/wk) and ribavirin (100

16 (HCV) genotype 1 infection were treated with peginterferon alfa-2a (180 microg/wk) and ribavirin (100

17 Patients randomized to the highest doses of peginterferon alfa-2a (270 microg/week) and ribavirin (1

18 Higher fixed doses of peginterferon alfa-2a (270 microg/week) and ribavirin (1

19 Among patients receiving peginterferon alfa-2a (270 microg/week) the magnitude of

20 During treatment, patients receiving peginterferon alfa-2a (40 kd) had statistically signific

21 e of sustained virological response (SVR) to peginterferon alfa-2a (40 kd) in combination with ribavi

22 open-label, randomized studies that compared peginterferon alfa-2a (40 kd) with interferon alfa-2a.

23 otent second-generation protease inhibitor), peginterferon alfa-2a (40 KD), and ribavirin in these pa

24 ith polyethylene glycol-modified interferon (peginterferon) alfa-2a (40 kd) provides improved sustain

25 in which patients received mericitabine plus peginterferon alfa-2a (40KD)/ribavirin were analyzed by

26 se of HALT-C trial were randomized to either peginterferon alfa-2a (90 microg/week) maintenance thera

27 irin (56 percent vs. 44 percent, P<0.001) or peginterferon alfa-2a alone (56 percent vs. 29 percent,

28 irin, interferon alfa-2b plus ribavirin, and peginterferon alfa-2a alone in the initial treatment of

29 Treatment with peginterferon alfa-2a alone produces significantly highe

30 ed with interferon alfa-2b plus ribavirin or peginterferon alfa-2a alone.

31 Simeprevir once daily with peginterferon alfa 2a and ribavirin shortens therapy in

32 bination therapy with pegylated interferons (peginterferon alfa-2a and alfa-2b) yields an adverse eve

33 Synergy was observed between R1626 and peginterferon alfa-2a and between R1626 and ribavirin.

34 8 hours thereafter) for 12 weeks, as well as peginterferon alfa-2a and ribavirin (at the same doses a

35 daily) alone (Group A, 11 patients) or with peginterferon alfa-2a and ribavirin (Group B, 10 patient

36 group A, 11 patients) or in combination with peginterferon alfa-2a and ribavirin (group B, 10 patient

37 were randomized 2:1:1 to receive 48 weeks of peginterferon alfa-2a and ribavirin (PegIFN/RBV) in comb

38 ty of 2 weeks therapy with telaprevir alone, peginterferon alfa-2a and ribavirin (PR), or all 3 drugs

39 essed virologic response to retreatment with peginterferon alfa-2a and ribavirin (RBV), as a function

40 or 12 weeks; patients were then treated with peginterferon alfa-2a and ribavirin alone for 12 weeks i

41 bavirin for 12 weeks followed by 36 weeks of peginterferon alfa-2a and ribavirin alone.

42 rin was more effective than retreatment with peginterferon alfa-2a and ribavirin alone.

43 previous null responders with simeprevir and peginterferon alfa-2a and ribavirin and telaprevir and p

44 of sustained virologic response (SVR) after peginterferon alfa-2a and ribavirin combination therapy

45 : a group receiving telaprevir combined with peginterferon alfa-2a and ribavirin for 12 weeks (T12PR

46 vir placebo (once a day) in combination with peginterferon alfa-2a and ribavirin for 12 weeks followe

47 mg twice daily or 750 mg every 8 hours plus peginterferon alfa-2a and ribavirin for 12 weeks; patien

48 Nonresponders with HCV genotype 1 were given peginterferon alfa-2a and ribavirin for 2 weeks (course

49 responders to interferon were retreated with peginterferon alfa-2a and ribavirin for 24 (n=177) or 48

50 y for 12 weeks followed by nitazoxanide plus peginterferon alfa-2a and ribavirin for 36 weeks (n = 28

51 group, receiving telaprevir for 24 weeks and peginterferon alfa-2a and ribavirin for 48 weeks (at the

52 ts to the PR48 (or control) group, receiving peginterferon alfa-2a and ribavirin for 48 weeks (at the

53 to groups that were given standard of care (peginterferon alfa-2a and ribavirin for 48 weeks, n = 40

54 , all 10 (100%) who received sofosbuvir plus peginterferon alfa-2a and ribavirin for 8 weeks had a su

55 monotherapy for 12 weeks or sofosbuvir plus peginterferon alfa-2a and ribavirin for 8 weeks.

56 ribavirin was non-inferior to telaprevir and peginterferon alfa-2a and ribavirin for SVR12 (54% [203/

57 istered a 12-week regimen of sofosbuvir plus peginterferon alfa-2a and ribavirin in 327 patients with

58 designed to test the efficacy and safety of peginterferon alfa-2a and ribavirin in children, provide

59 to HCV genotype 1 who underwent therapy with peginterferon alfa-2a and ribavirin in the Study of Vira

60 fferent dosages of R1626 in combination with peginterferon alfa-2a and ribavirin is underway.

61 Peginterferon alfa-2a and ribavirin therapy provides goo

62 ron alfa-2a and ribavirin and telaprevir and peginterferon alfa-2a and ribavirin treatment, respectiv

63 nders during at least one previous course of peginterferon alfa-2a and ribavirin treatment.

64 The efficacy of high-dose regimens of peginterferon alfa-2a and ribavirin was compared with co

65 reatment with telaprevir in combination with peginterferon alfa-2a and ribavirin was more effective t

66 Simeprevir and peginterferon alfa-2a and ribavirin was non-inferior to

67 Simeprevir once a day with peginterferon alfa-2a and ribavirin was well tolerated i

68 , and 900 mg every 12 hours) or placebo plus peginterferon alfa-2a and ribavirin, followed by peginte

69 atment with daclatasvir, in combination with peginterferon alfa-2a and ribavirin, is a well tolerated

70 chieved with only 16 weeks of treatment with peginterferon alfa-2a and ribavirin.

71 y can achieve SVR following retreatment with peginterferon alfa-2a and ribavirin.

72 , or 24 weeks of placebo, each combined with peginterferon alfa-2a and ribavirin.

73 cacy to telaprevir, each in combination with peginterferon alfa-2a and ribavirin.

74 nterferon alfa-2a and ribavirin, followed by peginterferon alfa-2a and ribavirin.

75 who were given placebo received 48 weeks of peginterferon alfa-2a and ribavirin.

76 d SVR48 after treatment intensification with peginterferon alfa-2a and ribavirin.

77 t-acting antiviral agents were combined with peginterferon alfa-2a and ribavirin.

78 BeAg seroconversion in patients treated with peginterferon alfa-2a and to assess the dynamic changes

79 ht >/=85 kg), a 12-week induction regimen of peginterferon alfa-2a and/or higher-dose ribavirin is no

80 a 2a, and ribavirin was superior to placebo, peginterferon alfa 2a, and ribavirin (SVR12 in 210 [80%]

81 Treatment with simeprevir, peginterferon alfa 2a, and ribavirin was superior to pla

82 atients treated with regimens that contained peginterferon alfa-2a, and anemia was more common among

83 The combination of nitazoxanide, peginterferon alfa-2a, and ribavirin increased the perce

84 The combination of danoprevir, peginterferon alfa-2a, and ribavirin leads to high rates

85 re randomized to double-blind treatment with peginterferon alfa-2a at 180 or 270 microg/week plus rib

86 conducted a randomized, controlled trial of peginterferon alfa-2a at a dosage of 90 microg per week

87 irin at a dose of 800 to 1400 mg per day, or peginterferon alfa-2a at a dose of 180 microg per week p

88 elaprevir at a dose of 750 mg every 8 hours, peginterferon alfa-2a at a dose of 180 mug per week, and

89 Late responders to peginterferon alfa-2a could also be differentiated from

90 Peginterferon alfa-2a could be an effective therapy for

91 Additional groups included 360 mug/wk peginterferon alfa-2a for 12 weeks then 180 mug/wk pegin

92 o the T24P24 group, receiving telaprevir and peginterferon alfa-2a for 24 weeks (at the same doses as

93 y for 12 weeks followed by nitazoxanide plus peginterferon alfa-2a for 36 weeks (n = 28), or nitazoxa

94 erferon alfa-2a for 12 weeks then 180 mug/wk peginterferon alfa-2a for 36 weeks plus 1200 mg/day riba

95 Three of these groups also received peginterferon alfa-2a for 4, 8, or 12 weeks.

96 Patients were randomized to 180 mug/wk peginterferon alfa-2a for 48 weeks plus 1200 mg/day riba

97 he treatment trial, 10 patients (30%) in the peginterferon alfa-2a group and 6 (19%) in the untreated

98 e prophylaxis trial, 8 patients (31%) in the peginterferon alfa-2a group and 9 (32%) in the untreated

99 Patients given nitazoxanide plus peginterferon alfa-2a had intermediate rates of RVR (54%

100 ecommend the use of peginterferon alfa-2b or peginterferon alfa-2a in combination with ribavirin for

101 rial--to evaluate the safety and efficacy of peginterferon alfa-2a in patients who had undergone OLT.

102 The strength of peginterferon alfa-2a-induced IFIG response significantl

103 Overall, 80% of patients received peginterferon alfa-2a monotherapy or peginterferon alfa-

104 either interferon alfa-2a plus ribavirin or peginterferon alfa-2a monotherapy.

105 DUAL 1500 (1500 mg R1626 twice daily [bid] + peginterferon alfa-2a; n = 21); DUAL 3000 (3000 mg R1626

106 -2a; n = 21); DUAL 3000 (3000 mg R1626 bid + peginterferon alfa-2a; n = 32); TRIPLE 1500 (1500 mg R16

107 tudy medication, consisting of 180 microg of peginterferon alfa-2a once weekly plus daily ribavirin (

108 3/4A protease inhibitor versus placebo, plus peginterferon alfa 2a or 2b plus ribavirin was assessed

109 lacebo group) for 12 weeks, followed by just peginterferon alfa 2a or 2b plus ribavirin.

110 evir group) or placebo (once daily, orally), peginterferon alfa 2a or 2b, plus ribavirin (placebo gro

111 Addition of simeprevir to either peginterferon alfa 2a or peginterferon alfa 2b plus riba

112 nt with once weekly injections of 180 microg peginterferon alfa-2a or no antiviral treatment for 48 w

113 Pegylated interferon (peginterferon) alfa 2a or 2b plus ribavirin regimens wer

114 w-dose peginterferon alfa-2b, and 40.9% with peginterferon alfa-2a (P=0.20 for standard-dose vs. low-

115 2a plus ribavirin for 12 weeks, followed by peginterferon alfa 2a plus ribavirin (placebo group).

116 2a plus ribavirin for 12 weeks, followed by peginterferon alfa 2a plus ribavirin (simeprevir group),

117 simeprevir (150 mg once daily, orally) plus peginterferon alfa 2a plus ribavirin for 12 weeks, follo

118 n (simeprevir group), or placebo orally plus peginterferon alfa 2a plus ribavirin for 12 weeks, follo

119 ly, oral HCV NS3/4A protease inhibitor, plus peginterferon alfa 2a plus ribavirin were assessed in tr

120 g the adverse event profiles associated with peginterferon alfa 2a plus ribavirin.

121 r 1200 mg, depending on body weight), weekly peginterferon alfa-2a plus daily placebo, or 3 million u

122 nfected HBeAg-positive patients who received peginterferon alfa-2a plus oral placebo for 48 weeks.

123 weekly subcutaneous injections of 180 microg peginterferon alfa-2a plus oral ribavirin (1000 mg/d for

124 rin (40 percent vs. 12 percent, P<0.001), or peginterferon alfa-2a plus placebo (40 percent vs. 20 pe

125 eron alfa-2a plus ribavirin, 14 percent with peginterferon alfa-2a plus placebo, and 7 percent with i

126 g per week) plus ribavirin (800 mg per day), peginterferon alfa-2a plus placebo, or interferon alfa-2

127 ve sofosbuvir plus ribavirin for 12 weeks or peginterferon alfa-2a plus ribavirin for 24 weeks.

128 y higher proportion of patients who received peginterferon alfa-2a plus ribavirin had a sustained vir

129 significantly higher among the recipients of peginterferon alfa-2a plus ribavirin than among those as

130 ed with both HIV and HCV, the combination of peginterferon alfa-2a plus ribavirin was significantly m

131 tients with chronic hepatitis C, once-weekly peginterferon alfa-2a plus ribavirin was tolerated as we

132 ined virologic response were 29 percent with peginterferon alfa-2a plus ribavirin, 14 percent with pe

133 We compared the efficacy and safety of peginterferon alfa-2a plus ribavirin, interferon alfa-2b

134 , underwent 48-week combination therapy with peginterferon alfa-2a plus ribavirin.

135 We evaluated intensified therapy with peginterferon alfa-2a plus ribavirin.

136 and safety of pegylated interferon alfa-2a (peginterferon alfa-2a) plus either ribavirin or placebo

137 d-dose peginterferon alfa-2b regimen and the peginterferon alfa-2a regimen.

138 erences among the 4 groups or between pooled peginterferon alfa-2a regimens (A + B vs C + D: odds rat

139 bavirin; n = 31); or standard of care (SOC) (peginterferon alfa-2a + ribavirin; n = 20).

140 a; n = 32); TRIPLE 1500 (1500 mg R1626 bid + peginterferon alfa-2a + ribavirin; n = 31); or standard

141 administered for 4 weeks in combination with peginterferon alfa-2a +/- ribavirin in HCV genotype 1-in

142 ct was observed when R1626 was combined with peginterferon alfa-2a +/- ribavirin; up to 74% of patien

143 tional study enrolling patients treated with peginterferon alfa-2a/ribavirin (PEG/RBV) with or withou

144 revir, an HCV NS3-4A protease inhibitor) and peginterferon alfa-2a/ribavirin (PR) in patients with ge

145 eceived peginterferon alfa-2a monotherapy or peginterferon alfa-2a/ribavirin combination therapy.

146 f black patients with chronic hepatitis C to peginterferon alfa-2a/ribavirin has demonstrated that tr

147 405 patients treated with mericitabine plus peginterferon alfa-2a/ribavirin in PROPEL and JUMP-C, vi

148 (PR48), combined with a total of 48 weeks of peginterferon alfa-2a/ribavirin.

149 depression was lower in the groups receiving peginterferon alfa-2a than in the group receiving interf

150 nths after completion of a 48-week course of peginterferon alfa-2a These responses remain durable in

151 Peginterferon alfa-2a treated patients had significantly

152 subset, a potential prognostic indicator in peginterferon alfa-2a-treated patients with HIV infectio

153 In conclusion, peginterferon alfa-2a treatment for 48 weeks is safe and

154 e randomly assigned to receive 180 microg of peginterferon alfa-2a weekly for 48 weeks, and 67 subjec

155 th HCV genotype 2 or 3 to receive 180 mug of peginterferon alfa-2a weekly, plus 800 mg of ribavirin d

156 The safety and efficacy of nitazoxanide plus peginterferon alfa-2a, with or without ribavirin, were e